AI Article Synopsis
- The meta-analysis investigates the link between polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD), highlighting inconsistent findings in previous studies.
- A total of 17 studies were analyzed, revealing that individuals with PCOS have a significantly higher risk of developing NAFLD compared to controls, especially among obese subjects and those with hyperandrogenism.
- While the data supports a connection between PCOS and NAFLD, the authors caution that the results are based on a limited number of studies and potential confounding factors, suggesting further research is needed.
Article Abstract
Background: Epidemiological literature regarding the effect of polycystic ovary syndrome (PCOS) as a risk factor for non-alcoholic fatty liver disease (NAFLD) remains inconsistent. Furthermore, it remains debatable whether NAFLD is associated with PCOS as a consequence of shared risk factors or whether PCOS contributes to NAFLD in an independent fashion. Therefore, this meta-analysis was conducted.
Methods: This meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Relevant studies published before May 2017 were identified and retrieved from PubMed and Web of Science databases. The data were extracted, and the pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.
Results: A total of 17 studies were included into the present analysis. Compared to the control group, the risk of NAFLD in the PCOS group was higher (OR = 2.25, 95% CI = 1.95-2.60). When stratified by BMI and geographic location, the results indicated that the frequency of NAFLD risk was significantly higher in obese subjects (OR = 3.01, 95% CI = 1.88-4.82), non-obese subjects (OR = 2.07, 95% CI = 1.12-3.85), subjects from Europe (OR = 2.00, 95% CI = 1.58-2.52), subjects from the Asia-Pacific Region, (OR = 2.32, 95% CI = 1.89-2.84) and subjects from America (OR = 2.96, 95% CI = 1.93-4.55). In addition, PCOS patients with hyperandrogenism (HA) had a significantly higher risk of NAFLD, compared with controls (OR = 3.31, 95% CI = 2.58-4.24). However, there was no association between PCOS patients without HA and higher risk of NAFLD (OR = 1.46; 95% CI =0.55-3.87). The results of this meta-analysis should be interpreted with caution due to the small number of observational studies and possible confounding factors.
Conclusion: The meta-analysis results suggest that PCOS is significantly associated with high risk of NAFLD. Although this association was independent of obesity and geographic region, it might be correlated with HA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946415 | PMC |
| http://dx.doi.org/10.1186/s12978-018-0519-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and Predictive Features of CT-Derived Nonalcoholic Fatty Liver Disease in Metabolically Healthy MACS.
Clin Endocrinol (Oxf)
January 2025
Gulhane Faculty of Medicine, Department of Endocrinology and Metabolism, University of Health Sciences, Ankara, Turkey.
Objective: Patients with mild autonomous cortisol secretion (MACS) are at increased risk of cardiometabolic outcomes, such as hyperglycemia, metabolic syndrome, and cardiovascular diseases. Nonalcoholic fatty liver disease (NAFLD) is also associated with increased cardiometabolic risk. We aimed to investigate the prevalence and predictors of NAFLD in metabolically healthy subjects with MACS.
View Article and Find Full Text PDFElevated GGT to HDL ratio as a marker for the risk of NAFLD and liver fibrosis.
Sci Rep
January 2025
Department of Geriatrics Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
This study investigated the association between NAFLD and liver fibrosis and the ratio of gamma-glutamyl transferase to high-density lipoprotein cholesterol (GGT/HDL-C). In this cross-sectional study, we included 4764 subjects who participated in the National Health and Nutrition Examination Survey (NHANES) during 2017-2018. Adjusted multivariate logistic regression analysis was utilized to evaluate the relationships between GGT/HDL-C levels and NAFLD, fatty liver degree, and liver fibrosis.
View Article and Find Full Text PDFCorrelation analysis of the triglyceride-glucose index and related parameters in metabolic dysfunction-associated fatty liver disease.
Sci Rep
January 2025
Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Street Taiping No.25, Region Jiangyang, Luzhou, 646099, Sichuan, China.
This study aimed to investigate the correlation and predictive value of TyG and related parameters with metabolic dysfunction-associated fatty liver disease (MAFLD) MAFLD. This study retrospectively included individuals who underwent health examinations and abdominal ultrasound from July 2021 to June 2024 at the Affiliated Hospital of Southwest Medical University, Sichuan Province, China. A total of 71,299 subjects' clinical and laboratory data were extracted, the correlation between TyG and related parameters and MAFLD was analyzed via univariate and multivariate logistic regression methods, and the nonlinear relationship between the TyG index and the risk of MAFLD was explored via restricted cubic spline (RCS) analysis.
View Article and Find Full Text PDFInfluence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus.
World J Hepatol
December 2024
Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Background: The effect of nonalcoholic fatty liver disease (NAFLD) on the efficacy of nucleoside analogues (NAs) in antiviral therapy for patients with chronic hepatitis B (CHB) remains controversial.
Aim: To investigate the influence of NAFLD on virological response in CHB patients undergoing NAs treatment.
Methods: Logistic regression analysis was conducted on a cohort of 465 CHB patients from two hospitals to determine whether NAFLD was a risk factor for adverse reactions to NAs.
Clinical profiles and their interaction of concurrent metabolic associated steatotic liver disease and hepatitis B virus infection.
World J Hepatol
December 2024
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan.
Background: A new nomenclature of metabolic associated steatotic liver disease (MASLD) was proposed in 2023, thus expanding the diagnostic name of "MASLD combined with other etiologies".
Aim: To investigate the clinical profiles of patients with concurrent MASLD and chronic hepatitis B virus (HBV) infection.
Methods: This study included participants from the Taiwan Bio-bank.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!